Introduction
============

The five-year survival rate is approximately 50% for oral squamous cell carcinoma (OSCC), which is one of the most common malignancies of the head and neck region ([@ref-6]; [@ref-13]; [@ref-22]; [@ref-23]; [@ref-42]). The predisposition of OSCC to distant metastases and metastases in the lymph nodes, its highly invasive nature, and its tendency towards local recurrence are important factors that contribute to the poor prognosis of OSCC patients ([@ref-27]; [@ref-35]). Hence, more effective novel tumor diagnostic and prognostic biomarkers ([@ref-28]), which can improve the survival rate and can be used to assess treatment outcomes, are urgently needed.

The Cancer Genome Atlas (TCGA) (<http://cancergenome.nih.gov>) database, which is primarily used to collate specimens from cancer patients and adjacent normal tissue specimens, contains large data sets collected with high-throughput methods at multiple genomic and proteomic levels ([@ref-7]; [@ref-43]). The Gene Expression Omnibus (GEO, <http://www.ncbi.nlm.nih.gov/geo/>) is the largest and most comprehensive public gene expression repository for high-throughput data at NCBI ([@ref-3]; [@ref-8]). Both the GEO and TCGA collect macroscopic clinical information, such as stage and grade of tumor, survival time, age, sex, and race. Therefore, the TCGA and GEO databases can be analyzed systematically and comprehensively to explore important potential value and information.

In this study, we first sought to use the existing GEO microarrays and TCGA RNA-seq data to identify differential expression of lncRNAs between OSCC and control tissue samples. Then, the differentially expressed lncRNAs were evaluated by Kaplan--Meier survival analysis and univariate, multivariate Cox proportional hazards regression analyses and Gene Set Enrichment Analysis (GSEA). Ultimately, through systematic and objective analysis, we first discovered that lncRNA [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4) is significantly associated with survival outcomes of OSCC patients based on TCGA data. Then, [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4) was further successfully confirmed as a potential prognostic biomarker for the prediction of overall survival (OS) in the GEO database. We hope that the lncRNA [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4) revealed in our study may serve as a novel biomarker and potential target for the diagnosis, treatment, and prognosis of OSCC.

Materials and Methods
=====================

Data source
-----------

The RNA-seq data and corresponding patient information data of head and neck cell carcinoma (HNSC) were downloaded from the TCGA database. Clinical samples from the oral cavity (buccal mucosa, tongue, lip, hard palate, alveolar ridge, floor of the mouth and oral cavity) were chosen, while some samples from other parts (hypopharynx, larynx, oropharynx and tonsil, for example) were excluded. The original microarray data between OSCC and adjacent normal tissue samples were downloaded from the NCBI GEO databases. The accession numbers were [GSE36820](GSE36820) and [GSE41613](GSE41613), respectively. The microarray data of [GSE36820](GSE36820) and [GSE41613](GSE41613) were based on [GPL570](GPL570) (Affymetrix Human Genome U133 Plus 2.0 Array).

Data pre-processing and differential expression analysis
--------------------------------------------------------

The edgeR package was downloaded from the Stanford University website. The original microarray data from the GEO were converted into expression measures using the affy R package. Then, the differentially expressed lncRNAs were identified by the Limma R package ([@ref-33]; [@ref-41]). The differentially expressed lncRNAs that were screened from the TCGA were analyzed by the edgeR package ([@ref-34]). To improve screen accuracy and simplify the screening process, the cut-off criteria, which was in accordance with the procedure of Benjamini & Hochberg (BH), was as follows: 1. the false discovery rate was controlled at 0.01; 2. the fold change should be more than 2. The differentially expressed lncRNAs among [GSE36820](GSE36820), [GSE41613](GSE41613) and the TCGA were identified by the intersect function in the R package. Tumor and normal tissue data were recorded and were statistically analyzed.

Identification of lncRNAs with prognostic value in OSCC
-------------------------------------------------------

The differences between expressed lncRNAs (fold change \>2, *p* \< 0.05) are involved in the prognostic value for OSCC. The OSCC patients were divided into two parts, depending on the average expression level of candidate lncRNAs: a high expression group and a low expression group. Survival differences and *p*-values were compared between the two groups and were evaluated using a Kaplan--Meier survival analysis and a log-rank test. After this, a univariate Cox proportional hazards regression analysis ([@ref-2]) was conducted to assess the correlation between candidate lncRNAs and patient overall survival (OS) and disease-free survival (DFS) (*p* \< 0.05). Statistically significant lncRNAs and clinical candidate predictors were further evaluated by multivariate Cox proportional hazards regression analyses to identify independent prognostic lncRNAs. Candidate predictors included age, gender, grade, and stage. We then performed subgroup analyses. The hazard ratio (HR) and 95% confidence interval (CI) were also assessed.

Gene set enrichment analysis (GSEA)
-----------------------------------

GSEA 2-2.2.3 (JAVA version) was downloaded from the Gene Set Enrichment Analysis website (<http://software.broadinstitute.org/gsea/index.jsp>). Then, the downloaded dataset was imported using the GSEA software. Gene sets identified as related to biological signal conduction on the MSigDB (Molecular Signatures Database) (<http://software.broadinstitute.org/gsea/msigdb>), which may be found on the GSEA website, served as reference gene sets. This process was repeated 1,000 times for each analysis according to the default weighted enrichment statistical method. Gene sets with a false discovery rate (FDR) \<0.25 and a family-wise error rate (FWR) \<0.05. The GSEA analysis includes four key statistics: Enrichment Score (ES), Normalized Enrichment Score (NES), False Discovery Rate (FDR) and *P*-value.

Statistical analysis
--------------------

In this study, all analyses, including the *t*-test, heat map, and survival analyses, were performed with the R, GraphPad and SPSS software packages. *p* values less than 0.05 were considered significant. All statistical tests were two-sided.

Results
=======

Characteristics of OSCC patients according to the TCGA
------------------------------------------------------

In this study, the datasets of 350 OSCC patient and 44 controls were acquired and downloaded from the TCGA (<http://cancergenome.nih.gov>) database; these datasets contained expression data and clinical information related to 14,448 lncRNAs. The clinicopathological features of all patients are shown in [Table 1](#table-1){ref-type="table"}. The mean ±  standard deviation (STDEV) for all patient ages is 61.590 ±  12.886.
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###### The clinicopathological characteristics of patients from the TCGA database.

![](peerj-06-5307-g007)

  Characteristics                   Number of case   No. of patients (%)
  --------------------------------- ---------------- ---------------------
  Age (years)                       346              
  ≦60                                                152(41.33%)
  ≧60                                                194(58.67%)
  Median (range)                                     61.590(19--90)
  Gender                            347              
  Male                                               236(68.01%)
  Female                                             111(31.99%)
  Alcohol history                   339              
  No                                                 111(32.74%)
  Yes                                                228(67.26%)
  Perineural invasion present       263              
  No                                                 123(46.77%)
  Yes                                                140(53.23%)
  Margin status                     324              
  Close                                              39(12.04%)
  Negative                                           244(75.31%)
  Positive                                           41(12.65%)
  Lymphovascular invasion present   250              
  Yes                                                76(30.40%)
  No                                                 174(69.60%)
  Tumor stage                       314              
  Stage I                                            21(6.69%)
  Stage II                                           56(17.83%)
  Stage III                                          64(20.38%)
  Stage IV                                           173(55.10%)
  T stage                           335              
  T1                                                 34(10.15%)
  T2                                                 103(%)
  T3                                                 70(%)
  T4                                                 128(%)
  N stage                           334              
  NO                                                 126(37.72%)
  N1                                                 52(15.57%)
  N2                                                 110(32.93%)
  N3                                                 46(13.77%)
  M stage                           170              
  M0                                                 125(73.53%)
  M1                                                 45(26.47%)
  Histologic grade                  344              
  G1                                                 53(15.41%)
  G2                                                 210(61.05%)
  G3                                                 71(20.64%)
  G4                                                 10(2.91%)
  Vital status                      347              
  Alive                                              227(65.42%)
  Dead                                               120(34.58%)

Significant differentially expressed lncRNAs in OSCC
----------------------------------------------------

In all, 2,493 differentially expressed lncRNAs were identified through analysis of 14,448 lncRNAs using the edgeR packages (fold change \>2, *p* \< 0.05) ([Fig. 1](#fig-1){ref-type="fig"}). Moreover, 855 lncRNAs were down-regulated and 1,638 lncRNAs were up-regulated in the OSCC samples compared to normal tissue. Down-regulated and up-regulated lncRNAs account for 34.2% and 65.6% of the differentially expressed lncRNAs, respectively.

![A heat map drawn to show differential lncRNA expression in OSCC and normal tissue samples from the TCGA datasets, which were analyzed with R software.\
Representative genes of each cluster were selected and represented as a heat map. Genes shown in red are upregulated and genes in blue are downregulated. The magnitude of the regulation is illustrated by the intensity of the color.](peerj-06-5307-g001){#fig-1}

Identification of survival differences lncRNAs in OSCC
------------------------------------------------------

We used a Kaplan--Meier survival analysis with the log-rank test to identify relationships between the above 2,493 lncRNA signatures and the survival of OSCC patients. Then, we determined the levels of 21 lncRNA signatures that were significantly related to OS and DFS. Among these 21 lncRNAs, a significant positive correlation was observed between the signatures of 13 lncRNAs (TTC39A-AS1, RP11-93B14.9, [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4), RP11-87C12.5, RP11-464F9.21, LINC01549, RP11-897M7.1, [AP003900.6](http://feb2014.archive.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000271308;r=21:11169720-11184046), LINC01343, RP11-181E10.3, CTD-2545H1.2, RP11-796E2.4 and LINC01108) and OS/DFS. In contrast, the signatures of the remaining 8 lncRNAs ([AC007879.2](http://www.ncbi.nlm.nih.gov/nuccore/AC007879.2), BOK-AS1, CTB-161M19.4, CTD-2033A16.3, FAM95B1, RP11-1C8.7, RP11-285G1.14 and RP11-286E11.1) were significantly negatively correlated with OS and DFS. That is, low expression of the 13 lncRNAs described above correlated with a poor prognosis of OSCC patients, while the up-regulation of the latter 8 lncRNAs correlated with a shorter survival time ([Fig. 2](#fig-2){ref-type="fig"}) ([Table 2](#table-2){ref-type="table"}).

![Kaplan--Meier survival analyses and log-rank tests for OS and DFS in OSCC.\
(A) OS and (B) DFS rates of all patients according to [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4) expression. (C) OS and (D) DFS rates of all patients according to [AP003900.6](http://feb2014.archive.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000271308;r=21:11169720-11184046) expression. (E) OS and (F) DFS rates of all patients according to BOK-AS1 expression. (G) OS and (H) DFS rates of all patients according to LINC01108 expression. (I) OS and (J) DFS rates of all patients according to RP11-1C8.7 expression. (K) OS and (L) DFS rates of all patients according to RP11-87C12.5 expression.](peerj-06-5307-g002){#fig-2}
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###### Twenty-one lncRNA levels significantly correlated to OS and DFS.

![](peerj-06-5307-g008)

  LncRNA                                                                                                                        Gene ID           Chromosome   OS (*P* value )   DFS (*P* value )
  ----------------------------------------------------------------------------------------------------------------------------- ----------------- ------------ ----------------- ------------------
  [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4)                                                                  ENSG00000230790   chr2         0.00987           0.00828
  [AP003900.6](http://feb2014.archive.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000271308;r=21:11169720-11184046)   ENSG00000271308   chr21        0.00868           0.00397
  BOK-AS1                                                                                                                       ENSG00000234235   chr2         0.01812           0.01597
  LINC01108                                                                                                                     ENSG00000226673   chr6         0.00631           0.00767
  RP11-1C8.7                                                                                                                    ENSG00000271830   chr8         0.00035           0.04009
  RP11-87C12.5                                                                                                                  ENSG00000255856   chr12        0.01058           0.00048
  TTC39A-AS1                                                                                                                    ENSG00000261664   chr1         0.04276           0.00371
  RP11-93B14.9                                                                                                                  ENSG00000277496   chr20        0.01279           0.00352
  [AC007879.2](http://www.ncbi.nlm.nih.gov/nuccore/AC007879.2)                                                                  ENSG00000234902   chr2         0.00811           0.03607
  RP11-464F9.21                                                                                                                 ENSG00000234606   chr10        0.01486           0.03221
  LINC01549                                                                                                                     LINC01549         chr21        0.00021           0.0165
  CTB-161M19.4                                                                                                                  ENSG00000249494   chr5         0.04807           0.01152
  RP11-286E11.1                                                                                                                 ENSG00000245293   chr4         0.03618           0.0041
  RP11-897M7.1                                                                                                                  ENSG00000256209   chr12        0.03129           0.02265
  LINC01343                                                                                                                     ENSG00000237290   chr1         0.01115           0.03191
  FAM95B1                                                                                                                       ENSG00000223839   chr9         0.04778           0.01648
  RP11-181E10.3                                                                                                                 ENSG00000271590   chr2         0.00597           0.00934
  CTD-2545H1.2                                                                                                                  ENSG00000262445   chr17        0.02892           0.02929
  RP11-796E2.4                                                                                                                  ENSG00000245904   chr12        0.04276           0.00371
  CTD-2033A16.3                                                                                                                 ENSG00000262136   chr16        0.04586           0.02714
  RP11-285G1.14                                                                                                                 ENSG00000273363   chr10        0.01276           0.00503

Through the above Kaplan--Meier survival analysis, the variables of age, gender, grade, tumor stage, and TNM stage were identified as statistically significant factors that are related to the above 21 lncRNAs and patient prognosis. We also applied univariate and multivariate Cox regression analyses to evaluate the ability of 21 candidate lncRNA signatures to serve as independent prognostic variables. The univariate analysis indicated that decreased [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4) expression (HR = 0.706, 95% CI \[0.551--0.903\], *p* = 0.006), age, tumor stage, and TNM stage were all significantly related to worse OS in OSCC patients ([Table 3](#table-3){ref-type="table"}). Decreased [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4) expression (HR = 0.601, 95% CI \[0.423--0.853\], *p* = 0.004) was the only variable that could predict poorer DFS for OSCC. Finally, multivariate Cox regression analysis revealed that low expression of [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4) was the only independent prognostic variable for both OS (HR = 0.672, 95% CI \[0.523--0.863\], *p* = 0.002) and DFS (HR = 0.600, 95% CI \[0.423--0.851\], *p* = 0.004) in OSCC patients ([Table 4](#table-4){ref-type="table"}). In addition, age and N stage were highly significantly correlated with shorter OS or DFS.
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###### Univariate and multivariate Cox regression analysis for OS in patients with OSCC.
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  Variables                                                      Univariate analysis   Multivariate analysis                                  
  -------------------------------------------------------------- --------------------- ----------------------- -------------- ------- ------- --------------
  Age (years)                                                    0.003                 1.021                   1.007, 1.036   0.001   1.026   1.011, 1.041
  Gender                                                         0.459                 1.150                   0.794, 1.665   0.481   1.145   0.786, 1.666
  Grade                                                          0.127                 1.215                   0.946, 1.560   0.062   1.276   0.988, 1.648
  Stage                                                                                                                                       
  (age ≦ 60)                                                     0.034                 1.425                   1.026, 1.978   0.210   0.765   0.503, 1.163
  (age \>  60)                                                   0.523                 1.080                   0.853, 1.367                   
  N                                                              0.015                 1.263                   1.046, 1.524   0.011   1.279   1.059, 1.546
  T (age ≦ 60)                                                   0.003                 1.551                   1.160, 2.075   0.293   1.101   0.921, 1.316
    (age \> 60)                                                  0.873                 0.982                   0.783, 1.230                   
  [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4)   0.006                 0.706                   0.551, 0.903   0.002   0.672   0.523, 0.863

**Notes.**

NRegional Lymph NodesTPrimary Tumor
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###### Univariate and multivariate Cox regression analysis for DFS in patients with OSCC.

![](peerj-06-5307-g010)

  Variables                                                      Univariate analysis   Multivariate analysis                                   
  -------------------------------------------------------------- --------------------- ----------------------- --------------- ------- ------- --------------
  Age (years)                                                    0.093                 1.017                   0.997, 1.036    0.071   1.018   0.999, 1.037
  Gender                                                         0.627                 1.132                   0.687, 1.867    0.678   1.113   0.672, 1.841
  Grade                                                          0.817                 1.043                   0.732, 1.485    0.533   1.125   0.777, 1.627
  Stage                                                          0.625                 1.064                   0.830, 1.363    0.482   0.852   0.545, 1.332
  N                                                              0.539                 1.085                   0.7837, 1.407   0.167   1.286   0.900, 1.836
  T                                                              0.191                 1.167                   0.926, 1.470    0.295   1.134   0.896, 1.434
  [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4)   0.004                 0.601                   0.423, 0.853    0.004   0.600   0.423, 0.851

lncRNA [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4) was low expressed in OSCC tissues and associated with clinicopathological parameters
--------------------------------------------------------------------------------------------------------------------------------------------------------

OSCC patients were further classified into high or low expression groups based on the median value of the relative lncRNA expression. The expression of lncRNA [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4) was significantly weaker in OSCC tissue samples (1.360 ± 0.05569) relative to normal tissue samples (3.062 ± 0.2304) in the TCGA (*p* \< 0.0001) ([Fig. 3](#fig-3){ref-type="fig"}). The correlation between lncRNA [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4) expression and clinicopathologic parameters of OSCC patients was also further analyzed. As shown in [Table 5](#table-5){ref-type="table"}, lncRNA [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4) expression was significantly correlated with alcohol history consumption (*p* = 0.033). Additionally, decreased expression of lncRNA [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4) expression was nearly significantly associated with T stage (*p* = 0.075). However, no significant association was found between other clinicopathological factors and lncRNA [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4) expression.

![Expression of [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4.) in normal tissues and OSCC tissues.\
[AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4) expression is significantly down-regulated in OSCC samples (1.360 ± 0.05569) in comparison to adjacent non-cancerous tissues (3.062 ± 0.2304) in the TCGA dataset.](peerj-06-5307-g003){#fig-3}
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###### [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4) expression and clinicopathological characteristics of patients with OSCC.
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  Characteristics   Number of case   [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4) expression   *P* value     
  ----------------- ---------------- ------------------------------------------------------------------------- ------------- -------
  Age (years)                                                                                                                0.082
  ≥60               186              96(51.61%)                                                                90(48.39%)    
  \<60              143              60(41.96%)                                                                83(58.08%)    
  Gender                                                                                                                     0.745
  Female            102              47(46.08%)                                                                55(59.92%)    
  Male              227              109(48.02%)                                                               118(51.98%)   
  Alcohol history                                                                                                            0.033
  Yes               213              109(51.17%)                                                               104(48.83%)   
  No                104              40(38.46%)                                                                64(61.54%)    
  M stage                                                                                                                    0,511
  M0                119              56(47.06%)                                                                63(52.94%)    
  M1                39               16(41.03%)                                                                23(58.97%)    
  T stage                                                                                                                    0.075
  T1  + T2          128              54(42.19%)                                                                74(57.81%)    
  T3  + T4          189              99(52.38%)                                                                90(47.62%)    
  N stage                                                                                                                    0.163
  N0  + N1          168              87(51.79%)                                                                81(48.21%)    
  N2  + N3          148              65(43.92%)                                                                83(56.08%)    

**Notes.**

M0No distant metastasis (no pathologic M0; use clinical M to complete stage group)M1Distant metastasisN0No regional lymph node metastasisN1Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimensionN2Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension; or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension; or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimensionN3Metastasis in a lymph node more than 6 cm in greatest dimensionT1Tumor 2 cm or less in greatest dimensionT2Tumor more than 2 cm but not more than 4 cm in greatest dimensionT3Tumor more than 4 cm in greatest dimensionT4aModerately advanced local diseaseT4bT4b Very advanced local disease

Tumor invades masticator space, pterygoid plates, or skull base and/or encases internal carotid artery.

Evaluation of the prognostic value of lncRNA [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4) via the GEO
---------------------------------------------------------------------------------------------------------------------

For the purpose of evaluating the robustness of lncRNA [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4) expression in the prediction of OS of OSCC patients, we acquired other independent datasets from the GEO with accession numbers of [GSE36820](GSE36820) and [GSE41613](GSE41613), which contained OSCC samples, but samples with incomplete clinical information were excluded. The prognostic signatures and the Kaplan--Meier analysis were calculated and performed for each OSCC sample. In agreement with the result of the TCGA datasets, low expression levels of lncRNA [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4) were associated with lower OS ([Fig. 4](#fig-4){ref-type="fig"}). The lncRNA [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4) was also expressed at low levels in OSCC tissues (*p* \< 0.0001).

![Evaluation of the prognostic value of lncRNA [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4) via the GEO.\
(A) Heatmap of lncRNA [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4) expression in GEO. (B) lncRNA [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4) expression was significantly low in OSCC. (C) OSCC patients were divided into the high expression group and the low expression group according to the median lncRNA [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4) expression. (D) The low expression of lncRNA [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4) was significantly associated with poor prognosis in patients with OSCC (*p* \< 0.0001).](peerj-06-5307-g004){#fig-4}

![KEGG pathway enrichment analysis of lncRNA [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4).\
(A) Enrichment of genes in the KEGG MAPK SIGNALING PATHWAY by GSEA. (B) Heat map of core enrichment genes in the gene set KEGG MAPK SIGNALING PATHWAY. (C) Enrichment of genes in KEGG PATHWAYS IN CANCER by GSEA. (D) Heat map of core enrichment genes from the gene set KEGG PATHWAYS IN CANCER. (E) Enrichment of genes in KEGG OXIDATIVE PHOSPHORYLATION by GSEA. (F) Heat map of core enrichment genes from the gene set KEGG OXIDATIVE PHOSPHORYLATION. (G) Enrichment of genes in KEGG SPLICEOSOME by GSEA. (H) Heat map of core enrichment genes from the gene set KEGG SPLICEOSOME. The GSEA software was used to calculate enrichment levels.](peerj-06-5307-g005){#fig-5}

![GSEA were carried out to identify upregulated or downregulated GO.\
(A) Enrichment of genes in GO ADAPTIVE IMMUNE RESPONSE by GSEA. (B) Heat map of core enrichment genes in the gene set GO ADAPTIVE IMMUNE RESPONSE. (C) Enrichment of genes in GO POSITIVE REGULATION OF CELL ACTIVATION by GSEA. (D) Heat map of core enrichment genes in the gene set GO POSITIVE REGULATION OF CELL ACTIVATION. (E) Enrichment of genes in GO RRNA METABOLIC PROCESS by GSEA. (F) Heat map of core enrichment genes in the gene set GO RRNA METABOLIC PROCESS. (G) Enrichment of genes in GO RIBOSOME BIOGENESIS by GSEA. (H) Heat map of core enrichment genes in the gene set GO RIBOSOME BIOGENESIS. The GSEA software was used to calculate the enrichment levels.](peerj-06-5307-g006){#fig-6}

Relationship between lncRNA [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4) and biological pathways and functions
------------------------------------------------------------------------------------------------------------------------------

Biological pathways and functions of lncRNA [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4) were identified by GSEA. This analysis revealed that lncRNA [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4) was involved in many critical pathways and correlated with tumorigenesis. A total of 150 pathways listed in the high-risk group were enriched, including KEGG MAPK SIGNALING PATHWAY, KEGG JAK-STAT SIGNALING PATHWAY, KEGG CALCIUM SIGNALING PATHWAY and KEGG PATHWAYS IN CANCER. Twenty-seven pathways in the low-risk group were also identified, including the KEGG OXIDATIVE PHOSPHORYLATION, KEGG PROTEASOME and KEGG SPLICEOSOME ([Fig. 5](#fig-5){ref-type="fig"}). Similarly, 3073 GO annotations in the high-risk group and 516 GO annotations in the low-risk group were enriched ([Fig. 6](#fig-6){ref-type="fig"}). Relevant partial results for KEGG pathways and GO analysis are listed in [Table 6](#table-6){ref-type="table"} and [Table 7](#table-7){ref-type="table"}.
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###### KEGG Pathways enriched in high-risk and low-risk groups by using GSEA.

![](peerj-06-5307-g012)

  NAME                                             SIZE   ES          NES         NOM p-val   FDR q-val   FWER p-val   Rank at max   Leading edge
  ------------------------------------------------ ------ ----------- ----------- ----------- ----------- ------------ ------------- --------------------------------
  KEGG_PRIMARY_IMMUNODEFICIENCY                    35     0.783950    2.003367    0.002036    0.080199    0.032        5022          tags=63%, list=9%, signal=69%
  KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION      258    0.503302    1.751613    0.016227    0.351688    0.258        13393         tags=46%, list=23%, signal=60%
  KEGG_JAK_STAT_SIGNALING_PATHWAY                  151    0.462485    1.585162    0.051020    0.356088    0.496        11252         tags=35%, list=19%, signal=43%
  KEGG_PATHWAYS_IN_CANCER                          324    0.296756    1.015304    0.442386    0.570524    0.968        12772         tags=28%, list=22%, signal=36%
  KEGG_MAPK_SIGNALING_PATHWAY                      265    0.353983    1.239951    0.226804    0.527153    0.881        11268         tags=29%, list=19%, signal=35%
  KEGG_PROTEASOME                                  46     −0.542264   −1.310828   0.249049    1           0.849        11204         tags=54%, list=19%, signal=67%
  KEGG_CYTOSOLIC_DNA_SENSING_PATHWAY               55     −0.342477   −1.059409   0.361581    1           0.958        6866          tags=33%, list=12%, signal=37%
  KEGG_SNARE_INTERACTIONS_IN_VESICULAR_TRANSPORT   38     −0.365953   −0.983674   0.481132    1           0.969        6863          tags=32%, list=12%, signal=36%
  KEGG_OXIDATIVE_PHOSPHORYLATION                   118    −0.269338   −0.724989   0.681050    1           0.992        11643         tags=38%, list=20%, signal=48%
  KEGG_SPLICEOSOME                                 123    −0.362891   −0.936620   0.566473    1           0.978        5025          tags=24%, list=9%, signal=26%
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###### GO annotation enriched in high-risk and low-risk groups by using GSEA.

![](peerj-06-5307-g013)

  Name                                                                          Size   ES         NES         NOM p-val   FDR q-val   FWER p-val   Rank at max   Leading edge
  ----------------------------------------------------------------------------- ------ ---------- ----------- ----------- ----------- ------------ ------------- --------------------------------
  GO_B\_CELL_RECEPTOR_SIGNALING_PATHWAY                                         54     0.749803   1.963207    0.003838    0.974954    0.161        6389          tags=67%, list=11%, signal=75%
  GO_ADAPTIVE_IMMUNE_RESPONSE                                                   279    0.614785   1.932954    0.007648    0.761521    0.202        7793          tags=46%, list=13%, signal=53%
  GO_NEGATIVE_REGULATION_OF_INTERLEUKIN \_6_PRODUCTION                          33     0.711452   1.897834    0           0.660863    0.28         10264         tags=67%, list=18%, signal=81%
  GO_REGULATION_OF_B\_CELL_ACTIVATION                                           121    0.626420   1.886616    0.003883    0.617897    0.294        9579          tags=55%, list=16%, signal=65%
  GO_POSITIVE_REGULATION_OF_CELL_ACTIVATION                                     305    0.540650   1.725436    0.031496    0.464684    0.631        11768         tags=47%, list=20%, signal=58%
  GO_CELLULAR_RESPONSE_TO_ZINC_ION                                              16     −0.60868   −1.550511   0.056310    1           0.883        4440          tags=56%, list=8%, signal=61%
  GO_RIBOSOMAL_LARGE_SUBUNIT_BIOGENESIS                                         48     −0.60318   −1.496404   0.109343    1           0.925        5330          tags=42%, list=9%, signal=46%
  GO_POSITIVE_REGULATION_OF_PEPTIDYL_SERINE \_PHOSPHORYLATION_OF_STAT_PROTEIN   21     −0.52630   −1.392874   0.115079    1           0.962        6411          tags=48%, list=11%, signal=53%
  GO_RRNA_METABOLIC_PROCESS                                                     249    −0.38387   −1.055244   0.457925    1           0.998        10606         tags=36%, list=18%, signal=44%
  GO_RIBOSOME_BIOGENESIS                                                        300    −0.38284   −1.050548   0.456692    1           0.998        11706         tags=38%, list=20%, signal=47%

Discussion
==========

OSCC is a common, highly invasive type of oral cancer prone to early recurrence and metastasis ([@ref-27]; [@ref-35]). Therefore, early diagnosis and treatment of OSCC is essential ([@ref-6]). While cytology- and pathology-based methods have been applied to the clinical differential diagnosis of OSCC, limitations in the detection methods and poor prognoses have limited the five-year survival rate ([@ref-29]). Hence, more reliable, accurate and sensitive prognosis biomarkers and tools for early diagnosis are urgently needed ([@ref-28]). In recent years, many studies have revealed a close association between aberrant expression of lncRNAs and tumorigenesis ([@ref-1]; [@ref-4]; [@ref-11]; [@ref-32]; [@ref-37]), which may aid in cancer diagnosis and prognosis.

Fewer than 2% of genes in the human genome are transcribed, and up to 98% of these transcripts are non-coding RNAs ([@ref-21]; [@ref-10]; [@ref-30]). lncRNAs are a class of non-coding transcripts ≥ 200 nucleotides in length that are actively involved in many biological processes, such as epigenetic regulation, cell cycle regulation, chromatin modulation and regulation of multiple gene expression ([@ref-32]; [@ref-44]). These non-coding transcripts also play key roles in the occurrence, development and progression of malignant tumors ([@ref-11]; [@ref-24]; [@ref-39]). An increasing number of studies have reported that lncRNAs can play essential roles as oncogenes or tumor suppressor genes involved in the development and progression of various cancers ([@ref-4]; [@ref-11]; [@ref-24]; [@ref-31]; [@ref-32]; [@ref-37]; [@ref-39]), including OSCC ([@ref-12]; [@ref-15]; [@ref-16]; ([@ref-26]). For example, the down-regulation of HOTAIR is associated with cancer progression in 26 human tumor types ([@ref-5]).

However, most early studies focused on a single gene or the results obtained from a single cohort study of lncRNAs and OSCC. [@ref-40] used qRT-PCR to analyze the expression levels of lncRNA PDIA3P in 58 OSCC and paired noncancerous tissue samples. This study found that the overexpression of lncRNA PDIA3P correlated with lower survival rates for OSCC patients. One study by [@ref-46] suggested that high expression of lncRNA HOTAIR in OSCC patients would contribute to the development and progression of cancer, leading to a poor prognosis. Similarly, LINC00668 expression is increased in both 50 OSCC tissues and cells, and over-expression is significantly correlated with poorer survival for OSCC patients; Therefore, this might be a negative predictive factor for the prognosis of OSCC patients ([@ref-47]). In the era of big data, the development of TCGA and GEO technology has allowed researchers to predict and identify new biomarkers, which has enhanced the reliability and accuracy of current research. [@ref-9] used TCGA and GEO data to determine that the expression levels of several lncRNAs, including RP1-228H13.5, TMCC1-AS1, LINC00205, and RP11-307C12.11, were associated with OS and recurrence-free survival of hepatocellular carcinoma patients. Three lncRNAs (LINC01140, TGFB2-OT1, and RP11-347C12.10) were significantly correlated with prognoses of hepatocellular carcinoma patients, independent of some clinical characteristics. Using the database, three lncRNAs, which may play key roles in the development, progression, and recurrence in gastric cancer, were identified ([@ref-38]). However, the functions, roles, and molecular mechanisms of lncRNAs associated with OSCC remain unclear.

In this study, we identified lncRNAs that are dysregulated in OSCC and evaluated the relationships between the TCGA database and the clinicopathological features of these OSCC patients. Based on the above analysis, a total of 21 lncRNAs were correlated with patient prognoses, of which 13 lncRNAs (TTC39A-AS1, RP11-93B14.9, [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4), RP11-87C12.5, RP11-464F9.21, LINC01549, RP11-897M7.1, [AP003900.6](http://feb2014.archive.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000271308;r=21:11169720-11184046), LINC01343, RP11-181E10.3, CTD-2545H1.2, RP11-796E2.4 and LINC01108) were significantly positively associated with OS and DFS, while the up-regulation of the latter eight lncRNAs ([AC007879.2](http://www.ncbi.nlm.nih.gov/nuccore/AC007879.2), BOK-AS1, CTB-161M19.4, CTD-2033A16.3, FAM95B1, RP11-1C8.7, RP11-285G1.14 and RP11-286E11.1) were correlated with poorer prognoses. [@ref-25] have also reported that RP11-1C8.7 predicted the progression and outcome of patients with kidney renal papillary cell carcinoma and was regarded as an independent prognostication factor for kidney renal papillary cell carcinoma. Thus far in the published literature, no report has evaluated the biological function and molecular mechanisms of other lncRNAs associated with human cancers.

To our knowledge, this study is pioneering research and identified the lncRNA [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4), which exhibited significantly lower expression in OSCC tissues than in adjacent normal tissues. Additionally, a Kaplan--Meier survival analysis ([@ref-17]) as well as univariate and multivariate Cox regression analyses revealed that lncRNA [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4) was an independent prognostic factor and was significantly correlated with shorter OS and DFS. Further validation via the GEO database was consistent with the TCGA database analysis results. Moreover, we further evaluated the relationship between [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4) expression and the clinicopathological features of OSCC patients. Low levels of [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4) were found to be significantly associated with the history of alcohol consumption in OSCC patients. Interestingly, according to previous studies, we found that alcohol consumption can increase the probability of G:C to A:T transitions and that alcohol drinkers exhibited a significantly higher incidence of p53 mutations in OSCC ([@ref-18]), which suggested that alcohol may play a critical role in the progression of OSCC.

Since lncRNAs perform their biological function by specifically binding to target genes, we further explored the possible biological functions and molecular pathways of [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4). Through GSEA, [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4) was found to be significantly involved with tumor-related signaling pathways and crucial biological functions in tumorigenesis. Key pathways and functions for tumor initiation and progression were identified, such as GO biological function annotation and KEGG pathways, including the adaptive immune response, RRNA metabolic processes, CALCIUM, MAPK, and the JAK/STAT signaling pathway. Additionally, mutation, aberrant expression and modification of these GO annotations and signaling pathways have been frequently reported in OSCC and other cancers. We found that the MAPK pathway could be activated by the low expression of the tumor suppressor QKI-5, which can promote the proliferation of OSCC cells ([@ref-14]). We also revealed the strong relationships between HOXC10 and gastric cancer cell proliferation and metastasis, which occur through the MAPK pathway ([@ref-16]). Other pathways and biological functions have also been reported in pancreatic ductal adenocarcinoma ([@ref-20]), hepatocellular carcinoma ([@ref-19]; [@ref-45]), and human papillomavirus-transformed tumors ([@ref-36]).

Dysregulated expression of lncRNA signatures has tremendous potential value, but this research has limitations. Above all, we have explored the correlation between [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4) expression and OSCC prognosis based on the TCGA and GEO databases, which signifies that the exploration was performed using a bioinformatics approach. Then, further research, such as quantitative real-time PCR, as well as *in vivo* and *in vitro* experiments, will require collaborative efforts to explore the potential molecular functions and related mechanisms of these lncRNAs in OSCC.

Conclusions
===========

In summary, this study was the first to discover that lncRNA [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4) was poorly expressed in OSCC, with decreased survival rates for OSCC patients. This may be a potential novel, independent biomarker and therapeutic target for the early diagnosis, pathological classification, clinical treatment and outcome prediction for OSCC. Nevertheless, these assumptions require validation and confirmation by larger, multicenter studies.
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###### All patients characteristics in OSCC from the TCGA database

The clinicopathological features of all OSCC patients from the TCGA database.

###### 

Click here for additional data file.
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###### Univariate and multivariate Cox regression analysis in patients with OSCC

Univariate and multivariate Cox regression analyses were applied to evaluate the 21 candidate lncRNA signatures as independent prognostic variables.

###### 

Click here for additional data file.
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###### Expression of AC012456.4 in normal tissues and OSCC tissues

AC012456.4 expression is significantly down-regulated in OSCC and normal tissue samples in the TCGA dataset.

###### 

Click here for additional data file.
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###### [AC012456.4](http://www.ncbi.nlm.nih.gov/nuccore/AC012456.4) expression and clinicopathological characteristics of patients with OSCC from the TCGA database

The relationship between the expression of lncRNA AC012456.4 OSCC tissues with clinicopathological parameters.

###### 

Click here for additional data file.
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###### Kaplan--Meier survival analyses and log-rank tests for DFS in OSCC

Kaplan--Meier survival analysis with the log-rank test was used to identify relationships between the above 2493 lncRNA signatures and OSCC patient survival. Then, we determined the levels of 126 lncRNA signatures that were significantly related to DFS.

###### 

Click here for additional data file.
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###### Kaplan--Meier survival analyses and log-rank tests for OS in OSCC

Kaplan--Meier survival analysis with the log-rank was used to identify relationships between the above 2493 lncRNA signatures and OSCC patient survival. Then, we determined the levels of 151 lncRNA signatures that were significantly related to OS.

###### 

Click here for additional data file.
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###### 21 lncRNA signatures that were significantly related to OS and DFS

Kaplan--Meierlan-Meier survival analysis with the log-rank was used to identify relationships between the above 2493 lncRNA signatures and OSCC patient survival. Then, we determined the levels of 21 lncRNA signatures that were significantly related to OS and DFS.

###### 

Click here for additional data file.
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###### KEGG Pathway enrichment analysis by GSEA

Biological pathways and functions of lncRNA AC012456.4 were identified by GSEA. This analysis revealed that lncRNA AC012456.4 was involved in many critical pathways and correlated with tumorigenesis.

###### 

Click here for additional data file.
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